Kinetics of C3 coating on RBCs in PNH patients receiving eculizumab. (A) Each line represents 1 of 5 newly diagnosed PNH patients starting treatment by eculizumab and followed longitudinally. (y-axis) Percentage of C3⁺ RBCs within PNH erythrocytes; (x-axis) weeks from start of treatment. (B) Each line represents 1 of 7 PNH patients longitudinally analyzed while on eculizumab treatment with a 2-year follow-up. (y-axis) Percentage of C3⁺ RBCs within PNH erythrocytes; (x-axis) months from start of treatment.